Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump

Pfizer said it anticipates sales of its Covid treatment Paxlovid and its vaccine will be $9 billion less than it had expected.

from Health and Science https://ift.tt/vhqPQoJ
https://ift.tt/81UPu96
https://ift.tt/sUMzlT8